[1] |
XIONG Weiyi, REN Jingtian.
Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
|
[2] |
PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu.
Exploring the significance of collecting patient reports based on international pharmacovigilance experience
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
|
[3] |
XIA Xudong, LI Meixia, SUN Yang, YANG Shengya.
Processes of remote inspection of pharmacovigilance for marketing authorization holders
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
|
[4] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[5] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[6] |
LEI Chao, QIAO Meng, CHEN Zijia, ZHANG Qiang, XIE Yanming, WANG Zhifei.
Revision of safety information in instructions of traditional Chinese patent medicines and simple preparations
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1396-1400.
|
[7] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B2 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1256-1258.
|
[8] |
JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang.
Evaluation index system of MAH pharmacovigilance work
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
|
[9] |
ZHONG Lumiao, DU Juan, DENG Hua, WANG Yafeng, QIU Ping, ZENG Linggui.
Thoughts on design and quality management of active safety surveillance research of traditional Chinese medicine injections initiated by Marketing Authorization Holder
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 994-998.
|
[10] |
LU Changfei, CUI Xiaokang, LIU Wenwen, ZHANG Huaqi, GAO Wenzheng, WU Shifu.
The Mechanism of monitoring of adverse drug reaction cluster signals and disposal at the provincial level
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 180-184.
|
[11] |
SONG Mingyue, ZHANG Ran, WU Zhiang.
Influencing factors of quality risk management of drug recall in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
|
[12] |
YANG Le, TIAN Chunhua, XIA Dongsheng, WANG Dan, LIU Cuili, TANG Ren, YU Hongli PENG Lili, WANG Gang.
Brief Introduction on the Guideline for the Pharmacovigilance Delegation Agreement (Pilot Version)
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 510-513.
|
[13] |
SHEN Mengqiu, LI Ming, WANG Jiayu, GAN Ge, LIU Pengcheng, SUN Jun.
Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 133-137.
|
[14] |
CHEN Cancan, CHEN Wei, ZHANG Yanan, HU Xiaoguang, LI Wanjun.
Thoughts on the Establishment of Pharmacovigilance System for Marketing Authorization Holders(MAHs)
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 474-479.
|
[15] |
WANG Xinhao, LU Xianping.
Thoughts on Establishment of Trans-disciplinary Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(3): 154-156.
|